CARVYKTI compares self -hematopoietic stem cell transplantation (ASCT) after administration of Daratumumab, Bortezomib, Lenalidomide, and DVRD in December last year. The clinical trial was conducted. According to the industry on the 8th, the Ministry of Food and Drug Safety recently completed the safety and validation of Carvykti. If the Efficacy & Safety screening is completed without any problems, product permission will be made soon.

CARVYKTI is a T -cell immunotherapy that is derived from BCMA targeted genetic variant. The US FDA has previously been allowed to treat reissue or rebel-resistant multiple myeloma adult patients with four or more treatments, including proteasome inhibitors, immunomodulat